Percutaneous ablation of malignant thoracic tumors

Ghaye, Benoît

doi:10.5334/jbr-btr.235

Cited by 2 publications

(1 citation statement)

References 54 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 3 ] In patients with stage I and II NSCLC and a favorable risk, surgical resection with lobectomy is recommended. However, only 15–30% of patients presenting with localized lung cancer are eligible for surgical resection due to various factors such as advanced age, co-morbidities, and poor cardiopulmonary reserve,[ 4 5 ] necessitating the development of alternative treatments. Although standard fractionation radiation therapy is a useful tool,[ 4 6 7 ] for patients with a poor pulmonary reserve, stereotactic body radiation therapy (SBRT) is needed.…”

Section: Introductionmentioning

confidence: 99%

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know

Bhatia

Pereira

Mohan

et al. 2016

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

Lung cancer continues to be one of the leading causes of death worldwide. In advanced cases of lung cancer, a multimodality approach is often applied, however with poor local control rates. In early non-small cell lung cancer (NSCLC), surgery is the standard of care. Only 15-30% of patients are eligible for surgical resection. Improvements in imaging and treatment delivery systems have provided new tools to better target these tumors. Stereotactic body radiation therapy (SBRT) has evolved as the next best option. The role of radiofrequency ablation (RFA) is also growing. Currently, it is a third-line option in stage 1 NSCLC, when SBRT cannot be performed. More recent studies have demonstrated usefulness in recurrent tumors and some authors have also suggested combination of RFA with other modalities in larger tumors. Following the National Lung Screening Trial (NLST), screening by low-dose computed tomography (CT) has demonstrated high rates of early-stage lung cancer detection in high-risk populations. Hence, even considering the current role of RFA as a third-line option, in view of increasing numbers of occurrences detected, the number of potential RFA candidates may see a steep uptrend. In view of all this, it is imperative that interventional radiologists be familiar with the techniques of lung ablation. The aim of this article is to discuss the procedural technique of RFA in the lung and review the current evidence regarding RFA for NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know

Bhatia

Pereira

Mohan

et al. 2016

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

show abstract

Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study

Liu

et al. 2015

Med Oncol

View full text Add to dashboard Cite

Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced lung cancer. The most common dose-limiting adverse effect of thoracic radiotherapy (RT) is radiation pneumonia (RP). A randomized comparison study was designed to investigate targeted percutaneous microwave ablation at pulmonary lesion combined with mediastinal RT with or without chemotherapy (ablation group) in comparison with RT (target volume includes pulmonary tumor and mediastinal node) with or without chemotherapy (RT group) for the treatment of locally advanced non-small cell lung cancers (NSCLCs). From 2009 to 2012, patients with stage IIIA or IIIB NSCLCs who refused to undergo surgery or were not suitable for surgery were enrolled. Patients were randomly assigned to the RT group (n = 47) or ablation group (n = 51). Primary outcomes were the incidence of RP and curative effectiveness (complete response, partial response, and stable disease); secondary outcome was the 2-year overall survival (OS). Fifteen patients (31.9%) in the RT and two (3.9%) in the ablation group experienced RP (P < 0.001). The ratio of effective cases was 85.1 versus 80.4% for mediastinal lymph node (P = 0.843) and 83.0 versus 100% for pulmonary tumors (P = 0.503), respectively, for the RT and ablation groups. Kaplan-Meier analysis demonstrated 2-year OS rate of NSCLC patients in ablation group was higher than RT group, but no statistical difference (log-rank test, P = 0.297). Percutaneous microwave ablation followed by RT for inoperable stage III NSCLCs may result in a lower rate of RP and better local control than radical RT treatments.

show abstract

Percutaneous ablation of malignant thoracic tumors

Cited by 2 publications

References 54 publications

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know

Targeted percutaneous microwave ablation at the pulmonary lesion combined with mediastinal radiotherapy with or without concurrent chemotherapy in locally advanced non-small cell lung cancer evaluation in a randomized comparison study

Contact Info

Product

Resources

About